Drug Trial Radar · NCT03105102
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,336
Actual
Start
Apr 9, 2018
Primary completion
Feb 2029
Study completion Feb 2029
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Apr 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study consists of 4 sub-studies, as follows: * Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety of risankizumab versus placebo as maintenance therapy in participants with moderately to severely active Crohn's disease (CD) who responded to intravenous risankizumab induction treatment in Study M16-006 or Study M15-991; * Sub-study 2 (Randomized, exploratory maintenance study) to evaluate the efficacy and safety of two different dosing regimens for risankizumab as maintenance therapy in participants who responded to induction treatment in Study M16-006 or Study M15-991; * Sub-study 3 (Open-label, long-term extension study) to evaluate long-term safety of risankizumab in participants who completed Sub-study 1, Sub-study 2, another AbbVie risankizumab Crohn's disease study, or participants who responded to induction treatment in Study M16-006 or Study M15-991 with no final endoscopy due to the Covid-19 pandemic. Additional objectives are to further investigate long-term efficacy and tolerability of risankizumab; * Sub-study 4 (Open-label On Body Injector (OBI) administration and long-term extension study) to evaluate patient-reported outcomes, efficacy, safety, tolerability, and pharmacokinetics of risankizumab administered via OBI in participants who are receiving maintenance treatment with risankizumab. * OL CTE to ensure uninterrupted care in accordance with local regulations until risankizumab is commercially available for participants who completed Sub-study 3, Sub-study 4.
Conditions
- Crohn's Disease
Interventions
Placebo for Risankizumab SCDrug
Placebo for Risankizumab SC Subcutaneous (SC) Injection
Risankizumab IVDrug
Risankizumab IV Intravenous (IV) infusion
Placebo for Risankizumab IVDrug
Placebo for Risankizumab IV Intravenous (IV) infusion
Risankizumab SCDrug
Risankizumab SC Subcutaneous (SC) injection
Risankizumab On-Body Injector (OBI)Drug
Subcutaneous (SC) injection; on-body injector (OBI)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sub-Study 1: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical RemissionTime frame: Week 52
- Sub-Study 1: Percentage of Participants With Endoscopic ResponseTime frame: Week 52
- Sub-Study 3: Number of Participants With Adverse EventsTime frame: Up to Week 220
- Sub-Study 4: Percentage of Participants With an Observer Rating of Successful Participant Self AdministrationTime frame: Up to Week 16
- Sub-Study 4: Percentage of Participants who had no Potential HazardsTime frame: Up to Week 16
- Sub-Study 4: Percentage of Participants Rating of Acceptability Using Self-Injection Assessment Questionnaire (SIAQ) at Weeks 0, 8, 16Time frame: Up to Week 16
- Sub-Study 4: Percentage of Participants in CDAI Clinical Remission at Week 0, 16Time frame: Up to Week 16
Locations
496 sites in 47 countries. Site status is shown where the registry gives one.
Digestive Disease Consultants, A Division of Arizona Digestive Health, P.C /ID# 211884
Mesa, Arizona
Phoenix VA Health Care System /ID# 162264
Phoenix, Arizona
Banner - University Medical Center Tucson /ID# 158502
Tucson, Arizona
Atria Clinical Research /ID# 164505
Little Rock, Arkansas
Southern California Res. Ctr. /ID# 211991
Coronado, California
Duplicate_Newport Huntington Medical Group /ID# 213035
Huntington Beach, California
UC San Diego Health Systems /ID# 155555
La Jolla, California
United Medical Doctors /ID# 207888
Los Alamitos, California
TLC Clinical Research Inc /ID# 212719
Los Angeles, California
Gastrointestinal Biosciences Clinical Trials /ID# 162657
Los Angeles, California
United Medical Doctors - Murrieta /ID# 158300
Murrieta, California
University of California San Francisco - Mission Bay /ID# 157127
San Francisco, California
Duplicate_Cedars-Sinai Medical Center-West Hollywood /ID# 163839
West Hollywood, California
Peak Gastroenterology Associates, PC /ID# 165843
Colorado Springs, Colorado
Rocky Mountain Pediatric Gastroenterology /ID# 207170
Lone Tree, Colorado
Duplicate_Western Connecticut Medical Group /ID# 165879
Danbury, Connecticut
Brandon Premier Health Care, PA/Gulf Coast Research Group, LLC /ID# 162262
Brandon, Florida
South Lake Pain Institute, Inc /ID# 162808
Clermont, Florida
Universal Axon Clinical Research /ID# 165428
Doral, Florida
Nature Coast Clinical Research - Inverness /ID# 159408
Inverness, Florida
SIH Research Mumtaz, Inc /ID# 163083
Kissimmee, Florida
Alliance Medical Research /ID# 163837
Lighthouse PT, Florida
Cfagi Llc /Id# 202479
Maitland, Florida
Sylvester Comprehensive Cancer Center /ID# 155007
Miami, Florida
Coral Research Clinic /ID# 158456
Miami, Florida
South Florida Research Ph I-IV, Inc. /ID# 161832
Miami, Florida
Gastroenterology Group Naples /ID# 165204
Naples, Florida
Advanced Research Institute, Inc /ID# 161966
New Port Richey, Florida
Endoscopic Research, Inc. /ID# 205906
Orlando, Florida
Omega Research - Orlando /ID# 171082
Orlando, Florida
IMIC Inc. Medical Research /ID# 154942
Palmetto Bay, Florida
Duplicate_Clinical Research of West Florida, Inc /ID# 208125
Tampa, Florida
Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 205865
Tampa, Florida
Atlanta Gastro Assoc /ID# 154724
Atlanta, Georgia
Gastroenterology Associates of Central Georgia, LLC /ID# 154850
Macon, Georgia
Duplicate_Northwestern University /ID# 158261
Chicago, Illinois
The University of Chicago Medical Center /ID# 157124
Chicago, Illinois
NorthShore University-Endeavor Health Evanston Hospital /ID# 158265
Evanston, Illinois
Southwest Gastroenterology /ID# 164781
Oak Lawn, Illinois
Cotton O'Neil Clinical Research Center, Digestive Health /ID# 154722
Topeka, Kansas
Showing 40 of 496 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.